Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real‐life practice
- 11 January 2019
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 180 (6) , 1551-1552
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab–clinical characteristics and treatmentThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthmaJournal of Allergy and Clinical Immunology, 2018
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaNew England Journal of Medicine, 2018
- Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical tBritish Journal of Dermatology, 2017
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- Current application of exhaled nitric oxide in clinical practiceJournal of Allergy and Clinical Immunology, 2016
- EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important differenceAllergy, 2011